Peter S. Ringrose

Biography

Dr. Peter Ringrose was appointed as Chair of the U.K. Government's Biotechnology and Biological Sciences Research Council (BBSRC) in 2003. He was Chief Scientific Officer of Bristol-Myers Squibb and President of the Pharmaceutical Research Institute. At BMS he was responsible for the development of aripiprazole (Abilify), cetuximab (Erbitux), atazanavir (Reyataz), gatifloxacin (Tequin), Entecavir, abatacept, ixabepilone and muraglitazar. Dr. Ringrose was Senior Vice President for Worldwide Drug Discovery and Medicinal R&D Europe with Pfizer. During his time at Pfizer, Dr. Ringrose was responsible for teams involved in the discovery and development of amlodipine (Norvasc), fluconazole (Diflucan), doxazosin (Cardura), sildenafil (Viagra), dofetilide (Tikosyn), darifenacin (Enablex), elitriptan (Relpax), voriconazole (Vfend). He was Division Director of Chemotherapy, Infectious Diseases and Molecular Sciences at the Sandoz Research Institute and held scientific positions with Hoffman La Roche. Dr. Ringrose has served on numerous scientific and educational advisory committees, including the Policy Advisory Board of the Centre for Medicines Research International, the Science and Regulatory Executive for PhRMA (Pharmaceutical Research and Manufacturers of America), the U.S. Council on Competitiveness, past-Chairman of the Hever Group of Pharmaceutical R&D Heads, the editorial board of Expert Opinion on Investigational Drugs, the Center for Advanced Biotechnology and Medicine New Jersey and the Association of British Pharmaceutical Industries (ABPI) Scientific Committee. He was a past Board member of Pfizer and of ImClone Systems Inc., and chaired the Europa Bio Congress session on new cancer therapies in Vienna 2003. He currently serves on the Board of Cambridge Antibody Technology as a non-executive director and is Chairman of CAT's Scientific Advisory Board and Remuneration Committee. He is also a non-executive director on the Boards of Astex Technology, Cambridge and Rigel Pharmaceuticals. He is a member of the SAB of Accenture Life Sciences and of Merlin Biosciences. Dr. Ringrose also serves on the Board of Governors of the New York Academy of Sciences, is a William Pitt Fellow of Pembroke College, Cambridge and Chair of the College Corporate Development Committee, is a member of the University of Cambridge Chemistry Advisory Board and was appointed to the Chancellor's Court of Benefactors at the University of Oxford in 1998. He is a Council Member of the Foundation for Science and Technology U.K. Dr. Ringrose gained his Master's degree and Ph.D. from the University of Cambridge (Corpus Christi College) in Biochemistry and Molecular Microbiology and was awarded the Francis Bacon scholarship.

Research Interest

Dr. Peter Ringrose was appointed as Chair of the U.K. Government's Biotechnology and Biological Sciences Research Council (BBSRC) in 2003. He was Chief Scientific Officer of Bristol-Myers Squibb and President of the Pharmaceutical Research Institute. At BMS he was responsible for the development of aripiprazole (Abilify), cetuximab (Erbitux), atazanavir (Reyataz), gatifloxacin (Tequin), Entecavir, abatacept, ixabepilone and muraglitazar. Dr. Ringrose was Senior Vice President for Worldwide Drug Discovery and Medicinal R&D Europe with Pfizer. During his time at Pfizer, Dr. Ringrose was responsible for teams involved in the discovery and development of amlodipine (Norvasc), fluconazole (Diflucan), doxazosin (Cardura), sildenafil (Viagra), dofetilide (Tikosyn), darifenacin (Enablex), elitriptan (Relpax), voriconazole (Vfend). He was Division Director of Chemotherapy, Infectious Diseases and Molecular Sciences at the Sandoz Research Institute and held scientific positions with Hoffman La Roche. Dr. Ringrose has served on numerous scientific and educational advisory committees, including the Policy Advisory Board of the Centre for Medicines Research International, the Science and Regulatory Executive for PhRMA (Pharmaceutical Research and Manufacturers of America), the U.S. Council on Competitiveness, past-Chairman of the Hever Group of Pharmaceutical R&D Heads, the editorial board of Expert Opinion on Investigational Drugs, the Center for Advanced Biotechnology and Medicine New Jersey and the Association of British Pharmaceutical Industries (ABPI) Scientific Committee. He was a past Board member of Pfizer and of ImClone Systems Inc., and chaired the Europa Bio Congress session on new cancer therapies in Vienna 2003. He currently serves on the Board of Cambridge Antibody Technology as a non-executive director and is Chairman of CAT's Scientific Advisory Board and Remuneration Committee. He is also a non-executive director on the Boards of Astex Technology, Cambridge and Rigel Pharmaceuticals. He is a member of the SAB of Accenture Life Sciences and of Merlin Biosciences. Dr. Ringrose also serves on the Board of Governors of the New York Academy of Sciences, is a William Pitt Fellow of Pembroke College, Cambridge and Chair of the College Corporate Development Committee, is a member of the University of Cambridge Chemistry Advisory Board and was appointed to the Chancellor's Court of Benefactors at the University of Oxford in 1998. He is a Council Member of the Foundation for Science and Technology U.K. Dr. Ringrose gained his Master's degree and Ph.D. from the University of Cambridge (Corpus Christi College) in Biochemistry and Molecular Microbiology and was awarded the Francis Bacon scholarship.